regardless of promising clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial difficulty from pharmacy benefit managers. Such insurers are typically creating obstacles to access, like high cost restrictions and prior authorization that hinder user availability. Marke